CellVoyant

R&D

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s

News

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.